SureTrader Stock Hero Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator binks, Seel
Search This Board:
Last Post: 4/24/2015 8:23:30 AM - Followers: 122 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for IDRA
IDRA News: Idera to Present at the 14th Annual Needham Healthcare Conference 04/13/2015 09:00:55 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 04/06/2015 04:20:04 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 04/03/2015 05:59:11 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 04/02/2015 07:10:40 PM
IDRA News: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma 04/01/2015 08:30:00 AM
PostSubject
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#1707   http://seekingalpha.com/article/3099106-idera-pharmaceuticals-is-the-writing-on- leakdog 04/24/15 08:23:30 AM
#1706   The question for IDRA now is double bottom Citrati 04/23/15 10:14:27 AM
#1705   back in this one, and ready to load rivervalley 04/21/15 03:15:13 PM
#1704   Thanks for that! Seel 04/20/15 09:37:26 PM
#1703   IDRA trying to finish putting in a bottom. Citrati 04/20/15 11:19:53 AM
#1702   IDRA is not presenting at AACR but one leakdog 04/18/15 01:04:11 PM
#1701   Thanks and best wishes for GREEN to you. Citrati 04/17/15 10:26:54 AM
#1700   Not just going to test 3.50 as was Citrati 04/17/15 10:24:24 AM
#1699   Took a starter here this morning. Good luck! Ebuilder 04/17/15 10:18:56 AM
#1698   Last time I checked it sounded like this etradeedge 04/16/15 11:39:29 PM
#1697   Out for now. Too many other good plays TheHound 04/14/15 01:20:38 PM
#1696   Anyone wishing a purchase price equivalent to Baker Citrati 04/14/15 09:50:08 AM
#1695   There's our 3.86 buy stop. Don't know how etradeedge 04/10/15 12:24:52 PM
#1694   I hear ha. Been watching and I think TheHound 04/09/15 12:12:24 AM
#1693   Would not surprise me. I think they are etradeedge 04/08/15 09:35:38 PM
#1692   Looks like you may have missed the mark TheHound 04/08/15 06:10:46 PM
#1691   Interesting to see Lou Brenner who was originally leakdog 04/08/15 02:44:21 PM
#1690   Ah, a Martin Pring follower. I remember reading Citrati 04/08/15 09:34:42 AM
#1689   Chart had a KST long term bullish indicator buckiii2 04/08/15 05:42:56 AM
#1688   Everyone is entitled to their tea leaf. The Citrati 04/08/15 01:27:24 AM
#1687   Certainly possible. That would be 2 steps back TheHound 04/08/15 12:35:24 AM
#1686   My tea leaf view is it's currently hanging etradeedge 04/07/15 10:26:56 PM
#1685   IDRA. buckiii2 04/07/15 10:07:05 PM
#1684   yes. Seel 04/07/15 08:19:01 PM
#1683   Risk is what makes life exciting and if binks 04/07/15 04:26:11 PM
#1682   $4.80 to $5. Target. Rollin ass backwards in TheHound 04/07/15 02:17:24 PM
#1681   Good deal. I was sweating it there for TheHound 04/07/15 01:11:10 PM
#1680   Looks to be building a base just above Citrati 04/07/15 10:35:38 AM
#1679   Really? How so..................LOL. etradeedge 04/06/15 11:49:27 PM
#1678   Hi there, I have been in IDRA almost stocking4ms 04/02/15 05:09:23 PM
#1677   Honestly I think the Orphan Status was a leakdog 04/02/15 08:36:52 AM
#1676   LOL, can't tell if that is expert opinion Citrati 04/01/15 11:55:10 PM
#1675   It's nothing more than a dead money wishful etradeedge 04/01/15 11:38:23 PM
#1674   Great news! Seel 04/01/15 08:24:57 PM
#1673   Can't say for sure, but a couple ideas. Citrati 04/01/15 03:40:09 PM
#1672   Wtf is wrong here, no move up uhh CBeeson 04/01/15 01:09:20 PM
#1671   General market and IBB red ink this morning Citrati 04/01/15 09:50:38 AM
#1670   NICE! Whohoo. Thanks C. I'm locked and loaded. TheHound 04/01/15 09:45:46 AM
#1669   Idera Announces FDA Orphan Drug Designation for IMO-8400 Citrati 04/01/15 09:27:13 AM
#1668   Making big bucks here! Go IDRA! TheHound 04/01/15 09:18:47 AM
#1667   Coming back Cbdpotential 03/31/15 01:57:40 PM
#1666   Rollin Rollin Rollin. Looking good!! TheHound 03/31/15 12:04:24 PM
#1665   back in today 3.64 binks 03/31/15 11:51:31 AM
#1664   yes, lets see if it can start a rivervalley 03/30/15 03:11:28 PM
#1663   looks good now nice price here around 3.50 binks 03/30/15 03:06:01 PM
#1662   Booooya! Go IDRA! TheHound 03/30/15 11:23:04 AM
#1661   will likely pick up some more shares early rivervalley 03/27/15 04:04:05 PM
#1660   Well I'm sitting really, really heavy right here TheHound 03/27/15 03:56:10 PM
#1659   Looks like we're going to test $3.30 again..... TheHound 03/27/15 10:18:22 AM
#1658   Thank you Citrati! Laughter soothes investing pains! Seel 03/26/15 01:28:53 PM
PostSubject